Biotech ETFs Tracking CRISPR Gene Editing Surge

A biotechnology exchange traded fund focusing on CRISPR gene editing bucked the broader market trends on Monday. Among the best performing non-leveraged ETFs of Monday, the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) advanced 7.1%. The ARK Genomic Revolution ETF tracks the convergence of...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.